Literature DB >> 9416294

The role of adenosine during the period of delayed cerebral swelling after severe traumatic brain injury in humans.

P M Kochanek1, R S Clark, W D Obrist, J A Carcillo, E K Jackson, Z Mi, S R Wisniewski, M J Bell, D W Marion.   

Abstract

Cerebrovascular failure with an increase in cerebral blood volume or hyperemia contributes delayed cerebral swelling after severe traumatic brain injury (TBI) in humans. One mediator that could be involved in this process is adenosine, which stimulates a concurrent reduction in cerebral metabolic rate and an increase in cerebral blood flow (CBF). We hypothesized that during the delayed phase after TBI in humans: 1) CSF adenosine concentration is associated with uncoupling of CBF and CMRO2, and 2) adenosine formation is driven by mediator-stimulated cAMP production in injured brain. We serially measured CBF and AVDO2, and CSF adenosine, lactate and cAMP after severe TBI in 13 humans. After 6-18 h, global CBF was increased and AVDO2 was reduced vs all other time periods, defining the uncoupling phase as the period between 18 h and 5 days. CSF adenosine concentration was negatively associated with AVDO2 and strongly associated with death (both p < 0.05), CSF lactate peaked during the initial 18 h, but remained increased for 5 days. CSF cAMP concentration was not increased (vs normal). The association between CSF adenosine concentration and death, and the correlation between uncoupling of CBF and oxidative metabolism and CSF adenosine concentration support our first hypothesis. In contrast, the low levels of cAMP in CSF observed in these patients, but persistently increased CSF lactate, refute our second hypothesis. We speculate that hyperglycolysis or occult ischemic foci are possible sources of ATP breakdown and adenosine formation, and that adenosine is playing a neuroprotective role.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416294     DOI: 10.1007/978-3-7091-6837-0_34

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  3 in total

1.  2',3'-cGMP exists in vivo and comprises a 2',3'-cGMP-guanosine pathway.

Authors:  Edwin K Jackson; Zaichuan Mi; Keri Janesko-Feldman; Travis C Jackson; Patrick M Kochanek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-02-21       Impact factor: 3.619

2.  Adenosine neuromodulation and traumatic brain injury.

Authors:  T A Lusardi
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

3.  NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia.

Authors:  Gene G Gurkoff; Jun-Feng Feng; Ken C Van; Ali Izadi; Rahil Ghiasvand; Kiarash Shahlaie; Minsoo Song; David A Lowe; Jia Zhou; Bruce G Lyeth
Journal:  Brain Res       Date:  2013-04-03       Impact factor: 3.252

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.